JP2021533115A5 - - Google Patents

Info

Publication number
JP2021533115A5
JP2021533115A5 JP2021505236A JP2021505236A JP2021533115A5 JP 2021533115 A5 JP2021533115 A5 JP 2021533115A5 JP 2021505236 A JP2021505236 A JP 2021505236A JP 2021505236 A JP2021505236 A JP 2021505236A JP 2021533115 A5 JP2021533115 A5 JP 2021533115A5
Authority
JP
Japan
Prior art keywords
aryl
alkyl
groups
substituted
alkenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021505236A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021533115A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/043868 external-priority patent/WO2020028222A1/en
Publication of JP2021533115A publication Critical patent/JP2021533115A/ja
Publication of JP2021533115A5 publication Critical patent/JP2021533115A5/ja
Pending legal-status Critical Current

Links

JP2021505236A 2018-07-29 2019-07-29 神経疾患またはミトコンドリア疾患の処置のための化合物 Pending JP2021533115A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862711575P 2018-07-29 2018-07-29
US62/711,575 2018-07-29
PCT/US2019/043868 WO2020028222A1 (en) 2018-07-29 2019-07-29 Compounds for the treatment of neurological or mitochondrial diseases

Publications (2)

Publication Number Publication Date
JP2021533115A JP2021533115A (ja) 2021-12-02
JP2021533115A5 true JP2021533115A5 (enExample) 2022-08-05

Family

ID=69232050

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021505236A Pending JP2021533115A (ja) 2018-07-29 2019-07-29 神経疾患またはミトコンドリア疾患の処置のための化合物

Country Status (6)

Country Link
US (2) US11771685B2 (enExample)
EP (1) EP3829560A4 (enExample)
JP (1) JP2021533115A (enExample)
KR (1) KR20210071949A (enExample)
CN (1) CN112770735A (enExample)
WO (1) WO2020028222A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021187314A1 (ja) * 2020-03-17 2021-09-23 学校法人福岡大学 ミトコンドリア機能障害改善剤
IT202100006065A1 (it) * 2021-03-15 2022-09-15 Univ Degli Studi Padova Composto per l’uso nel metodo di trattamento delle malattie mitocondriali da disfunzione dei complessi i, ii, iii della catena respiratoria

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4195998A (en) 1974-04-15 1980-04-01 Eastman Kodak Company CO(III) Complex containing radiation sensitive element with diazo recording layer
US5725871A (en) 1989-08-18 1998-03-10 Danbiosyst Uk Limited Drug delivery compositions comprising lysophosphoglycerolipid
US5707644A (en) 1989-11-04 1998-01-13 Danbiosyst Uk Limited Small particle compositions for intranasal drug delivery
US5466468A (en) 1990-04-03 1995-11-14 Ciba-Geigy Corporation Parenterally administrable liposome formulation comprising synthetic lipids
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
DK0590060T3 (da) 1991-06-21 1998-05-11 Univ Cincinnati Oralt indgivelige terapeutiske proteiner samt fremgangsmåde til fremstilling
US5756353A (en) 1991-12-17 1998-05-26 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol-and liposome-based delivery
ES2105262T3 (es) 1992-05-18 1997-10-16 Minnesota Mining & Mfg Dispositivo de suministro de farmaco a traves de las mucosas.
US5792451A (en) 1994-03-02 1998-08-11 Emisphere Technologies, Inc. Oral drug delivery compositions and methods
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
US5580579A (en) 1995-02-15 1996-12-03 Nano Systems L.L.C. Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers
IE80468B1 (en) 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
FR2742151B1 (fr) * 1995-12-12 1998-03-06 Innothera Lab Sa Utilisation de derives de bicycles mono ou dicetoniques, nouveaux composes obtenus et leur application en therapeutique
US6613308B2 (en) 2000-09-19 2003-09-02 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
WO2005053609A2 (en) * 2003-11-26 2005-06-16 Guilford Pharmaceuticals Inc. Methods of nad+-dependent deacetylase inhibitors
GB0816269D0 (en) 2008-09-05 2008-10-15 Univ Ramot Naphthoquinone derivatives useful for prevention of amyloid deposits and treatment of alzheimers disease
CN101712648B (zh) 2009-11-23 2011-11-09 南京大学 氮杂蒽醌的合成方法
WO2012019032A1 (en) * 2010-08-06 2012-02-09 Ampere Life Sciences, Inc. Treatment of mitochondrial diseases with vitamin k
SG187744A1 (en) * 2010-08-06 2013-03-28 Edison Pharmaceuticals Inc Treatment of mitochondrial diseases with naphthoquinones
US8980884B2 (en) 2011-06-01 2015-03-17 Wisconsin Alumni Research Foundation Methods for treating Alzheimer's disease
CN102321084B (zh) 2011-10-13 2013-03-13 南京大学 苯并[c]吡啶并[4,3,2-mn]吖啶-8-酮的合成方法
KR20140030786A (ko) 2012-09-03 2014-03-12 희성소재 (주) 신규한 화합물 및 이를 포함하는 유기전계발광소자
WO2014074976A1 (en) 2012-11-09 2014-05-15 Musc Foundation For Research Development Compositions and methods for treating neurological diseases or injury
US20150166476A1 (en) 2013-12-17 2015-06-18 Yi-Cheng Chen Methods for treating neurodegenerative diseases associated with aggregation of amyloid-beta
CN104761568B (zh) * 2014-01-03 2017-10-10 中国科学院上海药物研究所 一类四环萘并噁唑衍生物及其制备方法
WO2016040896A1 (en) 2014-09-12 2016-03-17 Pellficure Pharmaceuticals, Inc. Compositions and methods for treatment of prostate carcinoma
US10745350B2 (en) * 2015-07-30 2020-08-18 Calgent Biotechnology Co., Ltd. Compounds and pharmaceutical composition associated with ubiquitination-proteasome system

Similar Documents

Publication Publication Date Title
RU2483072C2 (ru) Производные фосфоновой кислоты и их применение в качестве антагонистов рецептора p2y12
JP2020515610A5 (enExample)
JP2021533115A5 (enExample)
JP2011509309A5 (enExample)
RU2009102278A (ru) Модуляторы рецептора s1p для лечения рассеянного склероза
JP2023508097A5 (enExample)
JP2022505841A5 (enExample)
JP2009526831A5 (enExample)
JP2018523665A5 (enExample)
JP2021530442A5 (enExample)
CA2206794A1 (fr) Nouveaux derives de 3,5-dioxo-(2h,4h)-1,2,4-triazines, leur preparation et leur application a titre de medicament
HU229935B1 (en) Dual action antibiotics
JP2022504620A5 (enExample)
JP2022527556A5 (enExample)
RU2018103873A (ru) Терапевтические соединения и композиции для лечения социальных расстройств и расстройств, связанных с употреблением психоактивных веществ
JP2013526520A5 (enExample)
RU2013120556A (ru) 1,2-гидрокси-2-оксо-хинолин-3-карбоксанилиды в качестве активаторов ahr
JP2021524439A5 (enExample)
JP2024539106A5 (enExample)
JP2024123258A (ja) 睡眠時無呼吸の治療のためのα２‐アドレナリン受容体サブタイプＣ （ＡＬＰＨＡ‐２Ｃ）拮抗薬
JP2023548342A5 (enExample)
JP2024546678A5 (enExample)
JOP20250101A1 (ar) مشتقات بنز إيميدازول حلقية كمثبطات cGAS
JP2021527650A5 (enExample)
BRPI0518615A2 (pt) derivados de malonamida